Evidence map›Paper›PMID 42277001›Full record

ArticleNature communications2026

Bacterial targeting of the neutrophil inhibitory receptor LILRB3 to evade antibody immunity.

Matevž Rumpret, Alexander L Lewis Marffy, Ying Zhang, Esther van Woudenbergh, Sjors P A van der Lans, Xin Xu, Zuyi Fu, Yuxi Zhao, Erin A Catton, Guillaume Paré and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Matevž Rumpret *Centre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-8631-8049
Alexander L Lewis Marffy *Centre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK.
Ying Zhang *Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.ORCID http://orcid.org/0009-0003-1603-7561
Esther van WoudenberghDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0001-7363-6649
Sjors P A van der LansDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Xin XuDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.ORCID http://orcid.org/0000-0002-0728-0821
Zuyi FuCentre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK.
Yuxi ZhaoDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Erin A CattonCentre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK.
Guillaume ParéDepartment of Microbiology and Immunology, Faculty of Medicine, Université Laval, Québec City, QC, Canada.
Felix McGregorCentre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK.
Owen B SpillerDepartment of Medical Microbiology, Division of Infection and Immunity, Cardiff University, 6th Floor University Hospital of Wales, Cardiff, UK.ORCID http://orcid.org/0000-0002-9117-6911
Maria J FernandesDepartment of Microbiology and Immunology, Faculty of Medicine, Université Laval, Québec City, QC, Canada.
Carla J C de HaasDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Jos A G van StrijpDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0001-6253-0830
Nina M van SorgeDepartment of Medical Microbiology and Infection Prevention, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2695-5863
Brian V GeisbrechtDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.ORCID http://orcid.org/0000-0002-1775-0727
Alex J McCarthyCentre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, Imperial College London, London, UK. a.mccarthy@imperial.ac.uk.ORCID http://orcid.org/0000-0002-4105-3737

Funding

Structure/Function Studies of LILRs Enabled by a Bacterially-Derived LigandR21AI155828 · NIAID · KANSAS STATE UNIVERSITY · PI GEISBRECHT, BRIAN V · 2021 to 2022
$380k
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Euratom (H2020 Euratom Research and Training Programme 2014-2018) 700862NIAID NIH HHS R21 AI155828RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/V006495/1United States Department of Agriculture | National Institute of Food and Agriculture (NIFA) Hatch Multistate Project KS23-0287-NC1202U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI155828Wellcome TrustWellcome Trust (Wellcome) 225315/Z/22/Z
6 · The paper itself

Abstract

Antibody-mediated responses are critical for antibacterial immunity, driving Fc receptor-mediated phagocytosis, respiratory burst, and bacterial killing. Inhibitory immune receptors regulate cellular activation and immune homoeostasis, but whether they are targeted to evade antibody-mediated responses is unclear. Here, we show that the highly expressed inhibitory LILRB3 receptor on neutrophils is targeted by Streptococcus agalactiae to suppress antibody-driven defence. We show that the surface-localised β protein of S. agalactiae bound to LILRB3 and induced its cross-linking. β and LILRB3 interactions suppressed Fc receptor-mediated antibacterial responses such as respiratory burst and bacterial killing, inhibiting antibody-dependent bacterial killing by neutrophils. Moreover, β expression and LILRB3 targeting are associated with S. agalactiae lineages that cause invasive diseases in older adults, indicating that targeting inhibitory receptors most likely provides an immune evasion mechanism when antibody responses are waning, such as in immunocompromised or elderly individuals. Altogether, these results highlight a simple and important mechanism that bacterial pathogens utilise to overcome effective antibody-driven phagocyte responses.

Indexed as

Antigens, CDImmune EvasionNeutrophilsReceptors, ImmunologicStreptococcal InfectionsStreptococcus agalactiaeAnimalsAntibodies, BacterialBacterial ProteinsHumansPhagocytosisRespiratory BurstAntibodies, BacterialAntigens, CDBacterial ProteinsLILRB3 protein, humanReceptors, Immunologic

Identifiers

PMID42277001
PMCPMC13408158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.